Search Results
Your search for can matches 13380 pages
Showing 2251 - 2300Biomarker Guidance May Allow Patients Aged 55 or Older With Low-Grade Luminal A–Type Breast Cancer to Avoid Radiation Therapy
Based on guidance from biomarker screening, patients with low-grade luminal A–type breast cancer aged 55 and older may need endocrine therapy alone following breast-conserving surgery and may be able to avoid radiation therapy entirely, according to new research findings presented by Timothy Joseph ...
Study Examines Ancestry-Specific Genetic Risk for Triple-Negative Breast Cancer
Although women of African descent experience a higher incidence and mortality from triple-negative breast cancer than women of other races or ethnicities, research findings presented by Hall et al at the 2022 ASCO Annual Meeting showed that the magnitude of gene-specific risks of triple-negative...
'Unprecedented' 100% of First 14 Untreated Patients With Rectal Cancer Respond to PD-1 Blocker Dostarlimab-gxly
Rarely, if ever, has one abstract presented at the ASCO Annual Meeting warranted its own session—but that happened with a small but mighty study from Memorial Sloan Kettering. In a study of patients with locally advanced mismatch repair–deficient (dMMR) rectal cancer, 6 months of treatment with the ...
Dabrafenib Plus Trametinib Improve Overall Response Rates vs Standard-of-Care Chemotherapy in Pediatric Patients With Low-Grade Gliomas
The combination of two targeted therapies, the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib, significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600...
Fam-Trastuzumab Deruxtecan-nxki Doubles Progression-Free Survival in HER2-Low Metastatic Breast Cancer
The use of fam-trastuzumab deruxtecan-nxki doubled progression-free survival compared with the standard-of-care treatment plus conventional chemotherapy. It also significantly improved overall survival for patients with metastatic breast cancers expressing low levels of the HER2 receptor,...
Panitumumab Plus mFOLFOX6 Improves Overall Survival in a Type of Newly Diagnosed Metastatic Colorectal Cancer
The use of panitumumab plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared with patients who received mFOLFOX6 plus bevacizumab, according to findings presented during the Plenary Session by...
Adagrasib Improves Outcomes in KRAS-Mutated NSCLC, Phase II Study Shows
Nearly 43% of patients with non–small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of...
ASCO and WHO to Collaborate on Quality Indicators for Cancer Facilities
In a collaboration announced today, ASCO will work with the World Health Organization (WHO) to measure and improve the quality of cancer care internationally. The goal is to achieve health-related targets of the United Nations Sustainable Development Goals and WHO Global Action Plan on...
ctDNA May Help Identify the Need for Adjuvant Therapy in Stage II Colon Cancer
In patients with stage II colon cancer where cancer DNA was not present in the blood (as circulating tumor DNA, or ctDNA), adjuvant chemotherapy could be skipped without compromising recurrence-free survival. Conversely, for patients where ctDNA was present after surgery, the rate of recurrence...
New Study Assesses Oncologists’ Ratings of the Importance of Health Insurance and Costs for Genomic Testing
A new study led by researchers at the American Cancer Society showed physician, practice, and patient characteristics were associated with oncologists’ ratings of the importance of patient health insurance and out-of-pocket costs for genomic testing in treatment decisions. The findings are being...
Jeremy Abramson, MD, Comments on Results From the SHINE Trial
Jeremy Abramson, MD, Director of the Jon and Jo Ann Hagler Center for Lymphoma at Massachusetts General Hospital Cancer Center and Associate Professor of Medicine at Harvard Medical School, was enthusiastic about these data. “These important data show that ibrutinib added to bendamustine/rituximab ...
Ibrutinib Added to Standard Therapy Prolongs Progression-Free Survival in Older Patients With Mantle Cell Lymphoma
Primary results from the phase III SHINE trial demonstrated that first-line treatment with ibrutinib combined with bendamustine/rituximab and rituximab maintenance achieves a substantial prolongation of progression-free survival in elderly patients with mantle cell lymphoma, according to a...
New Research Finds Computer-Assisted Colonoscopy May Identify More Precancerous Polyps Than Traditional Colonoscopy
Colonoscopies performed with computer-aided detection, or artificial intelligence (AI), saw an increase in the overall rate of detection of adenoma, or cancerous and precancerous polyps, by 27% in average-risk patients, according to new data presented by Shaukat et al at Digestive Disease Week 2022 ...
New Interactive Map of Oncology Puts COVID-19, Equity Data Into Perspective
In an effort to highlight cancer care inequities during the COVID-19 pandemic, ASCO has launched the Interactive Map of Oncology, a data visualization tool that allows users to explore geographic distribution of systemic and socioeconomic factors that influence cancer care delivery in the United...
A Global Humanist of Heroic Proportions Who Never Lost Sight of the Wounded Living in the Shadows of Poverty
Global health crusader Paul Farmer, MD, PhD, had a wildly unconventional childhood, which helped inform his adult life as a medical humanitarian. Dr. Farmer was born in West Adams, a town that lies along the verdant valley surrounding the Hoosic River in northern Massachusetts. He was the second of ...
City of Hope Researcher Receives Margaret L. Kripke Legend Award for Promotion of Women in Cancer
Leslie Bernstein, PhD, Director of City of Hope’s Division of Biomarkers of Early Detection and Prevention, received the Margaret L. Kripke Legend Award for Promotion of Women in Cancer Medicine and Cancer Science. Dr. Bernstein has made a substantial mark on both science and society by...
Turning Point
On a cool, gray November morning, I took the call from a walk-in doctor about Carla, a 26-year-old woman with progressive lymphadenopathy who was refusing investigations because of severe needle phobia. Carla was willing to meet with me to discuss treatment options for a suspected diagnosis of...
An International Leader Bridges the Political Divide in the Name of Humanity and Cancer Care
Michael Silbermann, DMD, PhD, was born on January 19, 1935, in the old quarter of Acre, a northern Arab city stretching along the north end of the Bay of Haifa in present-day Israel. “Acre, which was developed more than 4,000 years ago, was one of the primary harbors of the Phoenician people....
NCI Launches Program to Offer Molecular Characterization of Childhood Cancers
In support of President Biden’s Cancer Moonshot goal of fostering data sharing in cancer research, the National Cancer Institute (NCI), which is part of the National Institutes of Health, has launched the Molecular Characterization Initiative for pediatric tumors. This program offers tumor...
Growing Up in a House Filled With Science Leads to a Career in Breast Cancer and Health Outcomes Research
Debra Patt, MD, PhD, MBA, Executive Vice President of Policy and Strategic Initiatives for Texas Oncology, was reared in Plano, Texas, a city in the sprawling Dallas–Fort Worth metroplex. “My father was an electrical engineer with a PhD, and all throughout my childhood, I was exposed to the wonders ...
A Community Practitioner and Policy Advocate Who Stresses Holistic, Patient-Centered Care
Community practices have long been a keystone of our nation’s oncology care delivery system by allowing patients with cancer to receive specialized treatment near their homes and places of business. Innovative clinicians in the community setting are also leading efforts to create a more efficient...
A Nationally Regarded Pediatric Oncologist Found His Passion Early
ASCO Past President, Michael Link, MD, who has pioneered new strategies for treating common childhood cancers, was born and reared in a suburb of Cleveland. “My first significant exposure to medicine was my own family doctor, Dr. J.W. Epstein. Looking back, I was impressed by the combination of...
ASCO Expands Oncology Summer Internship Program With Aims to Increase Workforce Diversity
ASCO recently announced six additional medical schools will participate in the second year of the Oncology Summer Internship (OSI) program, an immersive, 4-week summer internship for rising second-year medical students from groups underrepresented in medicine (UIM).1 In 2022, ASCO and a total of 11 ...
Sunil Verma, MD, Navigates an International Path From Clinical Educator in Oncology to Leadership in Industry
In this installment of The ASCO Post’s Living a Full Life series, guest editor, Jame Abraham, MD, spoke with Sunil Verma, MD, the Global Head of Oncology, Medical, at AstraZeneca. Sunil Verma, MD, was born in Zambia, a landlocked country at the crossroads of Central, Southern, and East Africa. “My...
Navigating Difficult Waters: A Cancer Journey
In the summer of 2017, while visiting Normandy, 64-year-old Mark’s right testis became enlarged and tender. His initial workup identified a large testicular Leydig cell tumor with adverse pathologic features; computed tomography showed no evidence of metastasis.1,2 His medical history was otherwise ...
A Fascination With Bats Leads to a Career in Oncology and a Role in Championing Equity in the Workforce
According to internationally regarded neuroendocrine tumor specialist, Pamela Kunz, MD, her career path was kickstarted by childhood bat-hunting expeditions in barns and caves throughout rural New England. “My father was an environmental biologist at Boston University who studied bats. Although at...
Missed Opportunities in Geriatric Oncology Research
The underrepresentation of older patients (≥ 65 years) in clinical trials has been well documented for more than 20 years. This has been an issue at all phases of drug development, including pivotal trials for drug approvals,1 despite the fact that many of these new therapeutics will primarily be...
A Leader in Oncology Balances Philosophy, Medicine, and Humility
"The reality is that closure is a myth. My personal and professional experience with those who have lost friends and family, including children, has taught me that going on with life is not the same as gaining closure. The wound of loss is a part of each person’s life forever,” wrote...
A Son Forges a Noted Career in Oncology Rather Than Follow in His Father’s Illustrious Footsteps in Dermatology
Rakesh Chopra, MD, former Chairman and Head of the Oncology Department of Artemis Hospitals, was born in New Delhi, the capital of modern India. As a child, he attended the Lawrence School, Sanawar, a private boarding school in Himachal Pradesh, among beautiful sylvan surroundings. “Sanawar was...
ASCO Honors 2022 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2022 ASCO Annual Meeting in Chicago. “This year’s Special...
A Personal Cancer Journey Shifts a Career in the Arts to a Career in Radiation Oncology
It is safe to assume that most oncologists take a fairly straight career path, beginning with the decision to become a doctor. Along the educational journey from medical school to fellowship, an event or mentor usually incites the passion to pursue the challenging field of oncology. Although Fumiko ...
After Rounds on the Leukemia Ward, a Young Doctor Finds His Calling in Stem Cell Transplantation
Internationally recognized stem cell transplant pioneer Richard E. Champlin, MD, was born in Milwaukee and moved to Homewood, a suburb on the southern lip of Chicago, with his parents when he was 3 years old. Following high school, Dr. Champlin entered Purdue University in Indiana to pursue a...
ASCO’s President-Elect Makes Partnering With Patients the Cornerstone of His Presidential Term
This year, Eric P. Winer, MD, FASCO, takes on two new leadership roles in his illustrious medical career. In February, Dr. Winer left his positions as Chief Clinical Development Officer and Senior Vice President for Medical Affairs at Dana-Farber Cancer Institute, and Leader of the...
No Good Treatment Options, So I’ll Eat Ice Cream
On a warm summer afternoon, I stood in front of tables at the local farmers market loaded with my favorite fruits and vegetables: peaches, tomatoes, corn, peppers, melons, kale. I practically drooled thinking about what I could make that week: corn and tomato salad, kale and mushroom quesadillas,...
Multiple Myeloma: Treatment Conundrums
The availability of numerous new agents for treating multiple myeloma has created some “conundrums” for clinicians, said Sergio Giralt, MD, Deputy Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center and the Melvin Berlin Family Chair in Myeloma Research and...
Incidence of Cholelithiasis or Cholecystitis in the Year Prior to a Diagnosis of Pancreatic Ductal Adenocarcinoma
Patients with pancreatic ductal adenocarcinoma were six times more likely to have had gallstone disease within the year prior to diagnosis of pancreatic ductal adenocarcinoma than patients without cancer, according to research presented by Papageorge et al at Digestive Disease Week 2022 (Abstract...
Rise of Esophageal Cancer and Barrett’s Esophagus Rates in Middle-Aged Adults
Adults aged 45 to 64 years experienced a nearly doubled rate of esophageal cancer and a 50% increase in the precancerous condition Barrett’s esophagus between 2012 and 2019, according to a database analysis of roughly 5 million patients presented by Qumseya et al at Digestive Disease Week 2022...
Study Finds State Public Welfare Spending Was Associated With Improved 5-Year Overall Survival in Black Patients With Cancer
According to a recent report by The Commmonwealth Fund, “large racial and ethnic health inequities, driven by factors both inside and outside the health-care delivery system [in the United States], are common.” The result, according to the report, is that actions that could mitigate health...
Nearly Half of Black Patients With Metastatic Breast Cancer Report Not Being Informed About Clinical Trials
A survey of patients with metastatic breast cancer found that 83% of Black respondents were somewhat or very likely to consider clinical trial participation; however, 40% of those respondents reported that they had not been informed by their care team about the opportunity to enroll in a trial. The ...
Use of Telemedicine for Cancer Care Increased During the COVID-19 Pandemic but Varied by Race, Socioeconomic Status, and Other Factors
With the rapid acceleration of the spread of the COVID-19 virus in the United States in March 2020, telemedicine visits became more common for cancer care. However, in an evaluation of telemedicine inequities among patients with 21 common cancers, there were distinctly lower levels of telemedicine...
Incidental Respiratory Disease Found in Low-Dose CT Screens: Challenges and Opportunities
A retrospective analysis of the National Lung Screening Trial (NLST) by Pinsky et al, summarized in the April 25, 2022, issue of The ASCO Post, found high rates of incidental respiratory abnormalities on low-dose computed tomography (CT) examinations.1 Specifically, the findings of emphysema and...
Representatives Diana DeGette and Fred Upton Named ASCO Congressional Champions for Cancer Care
ASCO recently presented Representatives Diana DeGette (D-CO-1) and Fred Upton (R-MI-6) with the annual Congressional Champion for Cancer Care Award in recognition of their commitment to legislation that focuses on medical innovation. The award honors members of Congress who are leading champions...
ASCO Expands Oncology Summer Internship Program With Aims to Increase Workforce Diversity
ASCO recently announced six additional medical schools will participate in the second year of the Oncology Summer Internship (OSI) program, an immersive, 4-week summer internship for rising second-year medical students from groups underrepresented in medicine (UIM).1 In 2022, ASCO and a total of 11 ...
ASCO Guideline Rapid Update Addresses the Use of Neoadjuvant Pembrolizumab in High-Risk Early-Stage Triple-Negative Breast Cancer
A rapid update to the ASCO Guideline on neoadjuvant therapy for breast cancer adds a recommendation on the use of pembrolizumab in patients with high-risk early-stage triple-negative breast cancer.1 The update follows a recent analysis from the randomized phase III KEYNOTE-522 trial that showed a...
Innovation Can Advance Equitable Cancer Care
The North Star of an organization is its mission statement. At ASCO, no initiative gets the green light unless it can fulfill the Society’s mission. ASCO updated its mission statement in 2020 specifically to reinforce our goal of reducing disparities, changing it to read: “Conquering cancer through ...
An Emergency Room Physician Offers Hands-on Perspective for Treating Patients With Cancer
According to research in the literature, adults with cancer generate high rates of emergency department visits, leading to hospitalization roughly 60% of the time—nearly four times the rate of the general population. Although many of these visits could be prevented, this phenomenon offers numerable ...
A Second Edition Adds New Value to Personalized Medicine
Since the publication of the first draft of the human genome, genotyping and genomics have been integrated into standard clinical care for select cancers. But as precision medicine in oncology develops to comprise big data, proteomics, transcriptomics, molecular imaging, and more, there are...
Expert Point of View: David Paul Carbone, MD, PhD
“Progress in lung cancer happens by slow steps punctuated by quantum leaps. In the age of perioperative therapies, we are moving one step closer to curing more patients. Surgery is still the intervention most likely to cure patients with earlier-stage disease, but 50% of cases can recur,” said...
Long-Term Overall Survival in Unresectable Stage III NSCLC With Consolidation Durvalumab in the PACIFIC Trial: Translation to Real-World Outcomes?
Lung cancer mortality rates have declined by more than 50% in men since 1990 and more than 30% in women since 2002. These declines in mortality are largely due to increases in smoking cessation. However, in recent years, clinical treatment advances, such as targeted therapies and immunotherapy,...
PD-1 Inhibition in First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma: More to Come on New Paradigm
Esophageal cancer is associated with significant morbidity and mortality worldwide, with more than 600,000 new cases and 540,000 deaths in 2020. The squamous cell histology comprises nearly 90% of cases globally, despite its steady decline in the United States over the past 40 years. Historically,...
